A5060912167- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- CNS Lymphoma Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Esophageal Cancer Research and Treatment
- Oral and gingival health research
- Pediatric Hepatobiliary Diseases and Treatments
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Viral-associated cancers and disorders
- Metastasis and carcinoma case studies
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Renal cell carcinoma treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Helicobacter pylori-related gastroenterology studies
- Breast Lesions and Carcinomas
- Phagocytosis and Immune Regulation
University of Ulsan
2017-2025
Asan Medical Center
2017-2025
Ulsan College
2017-2025
Importance The NIFTY trial demonstrated the benefit of treatment with second-line liposomal irinotecan (nal-IRI) plus fluorouracil (FU) and leucovorin (LV) for patients advanced biliary tract cancer (BTC). Objective To report updated efficacy outcomes from extended follow-up 1.3 years reperformed masked independent central review (MICR) 3 newly invited radiologists. Design, Setting, Participants was a randomized, multicenter, open-label, phase 2b clinical conducted between September 5, 2018,...
Background No established biomarker exists for specific myeloid cell populations or in gastric cancer. This study aimed to explore the prognostic and immunological relevance of plasma translationally controlled tumor protein (TCTP) patients with advanced cancer treated an immune checkpoint inhibitor and/or cytotoxic chemotherapy. Methods Plasma samples were prospectively collected from cohorts first-line fluoropyrimidine plus platinum chemotherapy (n=143, cohort 1) third-line nivolumab...
We aimed to assess the efficacy of second-line fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer (BTC) after failure gemcitabine plus cisplatin (GEMCIS). retrospectively examined histologically documented BTC who received first-line GEMCIS between December 2010 and June 2015. Among 748 treated GEMCIS, 321 (43%) subsequently systemic chemotherapy. Fluoropyrimidine monotherapy fluoropyrimidine–platinum combination were used 255 66 patients, respectively. In...
474 Background: Cancer biomarkers are essential for determining the prognosis of disease and/or predicting its response to specific treatments. However, established representing myeloid cell populations and representative in gastric cancer remain unavailable. Therefore, this study aimed explore prognostic immunological relevance plasma translationally controlled tumor protein (TCTP) patients with advanced treated immune checkpoint inhibitor (ICI) cytotoxic chemotherapy. Methods: Plasma...
Liposomal irinotecan (nal-IRI) combined with fluorouracil (5-FU)/leucovorin (LV) as a second-line treatment for biliary tract cancer (BTC) following progression on gemcitabine-based therapy in the Korean NIFTY and German NALIRICC trials yielded conflicting outcomes. This necessitated comprehensive pooled analysis to evaluate its efficacy safety. Individual patient data were from intention-to-treat populations of trials. The primary endpoint was progression-free survival (PFS). A total 278...
Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis upfront surgery.This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. received 8 cycles of neoadjuvant modified (m) FOLFIRINOX. Up to 6 gemcitabine were given patients who underwent surgery. Plasma immune cell subsets measured analysing correlations overall (OS).Between May 2016 March 2018, 44 chemotherapy- radiotherapy-naïve...
<b><i>Background:</i></b> The incidence of intrahepatic cholangiocarcinoma (IHCCA) is rising around the world. disease becoming a major global health issue. Conventionally, most patients with present advanced and systemic therapy mainstay treatment. This review discusses recent advances in treatments for IHCCA. <b><i>Summary:</i></b> addition durvalumab to gemcitabine plus cisplatin regimen has significantly improved overall survival phase 3...
Purpose Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, BTC received up to 6-8 cycles of 3-weekly GemCis; however, those without progression often receive more than cycles. The clinical benefit maintenance treatment in uncertain. Materials and Methods Advanced treated GemCis between April 2010 February 2015 at Asan Medical Center, Seoul, Korea, were retrospectively analysed. after stratified...
Purpose Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability‒high (MSI-H) colorectal cancer (CRC), and factors predicting treatment not been fully identified. This study aimed to identify potential biomarkers of PD-1/PD-L1 inhibitor MSI-H CRC. Materials Methods CRC enrolled in three blockade at Asan Medical Center (Seoul, Republic Korea) were screened...
The clinical impact of 16α-
•We performed immune profiling of locally advanced pancreatic cancer treated with neoadjuvant therapy in a phase II trial.•Proportion programmed cell death protein 1-expressing peripheral CD8+ cells decreased after chemotherapy.•Lower monocytes and higher regulatory T were associated better progression-free survival.•Th1 pathway peritumoral longer disease-free survival from surgery.•Transforming growth factor-β MARCO expression early recurrence surgery. BackgroundA comprehensive analysis...
Purpose There are no reliable biomarkers to guide treatment for patients with borderline resectable pancreatic cancer (BRPC) in the neoadjuvant setting. We used plasma circulating tumor DNA (ctDNA) sequencing search BRPC receiving mFOLFIRINOX our phase 2 clinical trial (NCT02749136).Materials and Methods Among 44 enrolled trial, ctDNA at baseline or post-operation were included this analysis. Plasma cell-free isolation performed using Guardant 360 assay. Detection of genomic alterations,...
•We carried out a phase II basket trial of trastuzumab plus chemotherapy in HER2-positive solid tumors with ctDNA analysis.•Trastuzumab gemcitabine or irinotecan was safe and feasible for previously treated patients modest efficacy.•Plasma analysis useful detected HER2 amplification status other genomic profiles.•Our study indicates potential utility as biomarker patient selection future trials. BackgroundHuman epidermal growth factor receptor 2 (HER2) (ERBB2)-directed agents are standard...